The biological cost of mutational antibiotic resistance: any practical conclusions?

被引:329
作者
Andersson, Dan I. [1 ]
机构
[1] Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden
关键词
D O I
10.1016/j.mib.2006.07.002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A key parameter influencing the rate and trajectory of the evolution of antibiotic resistance is the fitness cost of resistance. Recent studies have demonstrated that antibiotic resistance, whether caused by target alteration or by other mechanisms, generally confers a reduction in fitness expressed as reduced growth, virulence or transmission. These findings imply that resistance might be reversible, provided antibiotic use is reduced. However, several processes act to stabilize resistance, including compensatory evolution where the fitness cost is ameliorated by additional mutation without loss of resistance, the rare occurrence of cost-free resistance mechanisms and genetic linkage or co-selection between the resistance markers and other selected markers. Conceivably we can use this knowledge to rationally choose and design targets and drugs where the costs of resistance are the highest, and where the likelihood of compensation is the lowest.
引用
收藏
页码:461 / 465
页数:5
相关论文
共 44 条
[1]   Multiresistant coagulase-negative staphylococci disseminate frequently between intubated patients in a multidisciplinary intensive care unit [J].
Agvald-Öhman, C ;
Lund, B ;
Edlund, C .
CRITICAL CARE, 2004, 8 (01) :R42-R47
[2]   Overexpression of the multidrug efflux pump SmeDEF impairs Stenotrophomonas maltophilia physiology [J].
Alonso, A ;
Morales, G ;
Escalante, R ;
Campanario, E ;
Sastre, L ;
Martinez, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (03) :432-434
[3]   The biological cost of antibiotic resistance [J].
Andersson, DI ;
Levin, BR .
CURRENT OPINION IN MICROBIOLOGY, 1999, 2 (05) :489-493
[4]   Persistence of antibiotic resistant bacteria [J].
Andersson, DI .
CURRENT OPINION IN MICROBIOLOGY, 2003, 6 (05) :452-456
[5]   Clonal spread of resistant pneumococci despite diminished antimicrobial use [J].
Arason, VA ;
Gunnlaugsson, A ;
Sigurdsson, JA ;
Erlendsdottir, H ;
Gudmundsson, S ;
Kristinsson, KG .
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 2002, 8 (03) :187-192
[6]   Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001 [J].
Bergman, M ;
Huikko, S ;
Pihlajamäki, M ;
Laippala, P ;
Palva, E ;
Huovinen, P ;
Seppälä, H .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (09) :1251-1256
[7]   Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus [J].
Besier, S ;
Ludwig, A ;
Brade, V ;
Wichelhaus, TA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) :1426-1431
[8]   Fitness cost due to mutations in the 16S rRNA associated with spectinomycin resistance in Chlamydia psittaci 6BC [J].
Binet, R ;
Maurelli, AT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4455-4464
[9]   Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori [J].
Björkholm, B ;
Sjölund, M ;
Falk, PG ;
Berg, OG ;
Engstrand, L ;
Andersson, DI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (25) :14607-14612
[10]   Isoniazid resistance and the future of drug-resistant tuberculosis [J].
Cohen, T ;
Becerra, MC ;
Murray, MB .
MICROBIAL DRUG RESISTANCE, 2004, 10 (04) :280-285